Celcuity Inc. Common Stock
CELC
$138.23
-3.02%
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumors, operating within the highly competitive oncology sector. The company's distinct identity is built on its lead candidate, gedatolisib, a kinase inhibitor targeting the PI3K/AKT/mTOR pathway with a mechanism designed to be differentiated from existing therapies, positioning it as a potential disruptor in treating HR+/HER2- breast cancer. The current investor narrative is overwhelmingly driven by the binary catalyst of upcoming FDA review and potential approval for gedatolisib, following the completion of enrollment in the pivotal Phase 3 VIKTORIA-1 trial, which has propelled the stock to extraordinary gains and attracted significant institutional investment betting on a successful commercial launch.…
CELC
Celcuity Inc. Common Stock
$138.23
Related headlines
Investment Opinion: Should I buy CELC Today?
Rating: Hold. The core thesis is that CELC is a purely speculative, binary bet on FDA approval where the extreme 1,185% price appreciation has likely front-run much of the positive outcome, creating asymmetric downside risk, while the majority analyst Buy rating and $1.72B average revenue target suggest fundamental optimism remains.
Supporting this Hold rating are several critical data points: the stock trades at a stratospheric Price-to-Book of 52.11, has zero revenue and negative margins, burns over $150M annually in cash, and yet maintains strong institutional conviction and a robust current ratio of 10.55 for liquidity. The forward PE of 186.80 is not meaningful due to lack of earnings, but the analyst revenue estimate range from $835M to $2.82B highlights the enormous uncertainty in commercial forecasts post-approval.
The thesis would upgrade to a Buy only on a significant pullback (e.g., towards the $100 support level) providing a better risk/reward entry, or upon confirmed positive FDA advisory committee news. It would downgrade to a Sell on any clinical setback, regulatory delay, or breakdown below key technical support. Relative to its own history and the binary nature of its business, the stock is dramatically overvalued on current financials but may be fairly valuing a successful approval scenario—the verdict rests entirely on an unpredictable regulatory event.
Sign up to view all
CELC 12-Month Price Forecast
The 12-month outlook for CELC is a textbook case of binary event investing, where the outcome distribution is wide but probabilities are difficult to assess. The base case (50% probability) of consolidation is most likely, as the staggering prior gains suggest the market has already assigned a high likelihood to approval. The bull case offers further upside but is capped by the need for flawless execution post-approval in a competitive market. The bear case, while lower probability, carries existential downside risk. The stance is neutral due to the asymmetric risk/reward at current prices; the favorable scenario is partially priced in, while the unfavorable one is not. This stance would turn bullish on a significant price correction providing a better entry point, or bearish on any negative regulatory developments.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celcuity Inc. Common Stock's 12-month outlook, with a consensus price target around $179.70 and implied upside of +30.0% versus the current price.
Average Target
$179.70
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$111 - $180
Analyst target range
Analyst coverage is active with 7 firms providing estimates, and the institutional ratings show a strongly bullish sentiment, with recent actions from Needham, Jefferies, Craig-Hallum, and Stifel all maintaining 'Buy' ratings, though a note of caution was introduced by HC Wainwright & Co. downgrading to 'Neutral' in November 2025. The average analyst revenue estimate for the forward period is $1.72 billion, with a wide range from a low of $835 million to a high of $2.82 billion, reflecting the high uncertainty around the timing and magnitude of potential commercial launch; this wide target spread signals low consensus conviction on the exact commercial outcome, which is typical for stocks facing a binary regulatory event.
Bulls vs Bears: CELC Investment Factors
The investment debate for CELC is a classic high-stakes binary bet, where bullish conviction on an imminent FDA approval clashes with bearish concerns over an extreme valuation built on zero revenue. The bull side currently has stronger momentum and institutional backing, as evidenced by the 1,185% annual gain and major fund investments betting on approval. However, the bear case is underpinned by concrete financial risks, including a massive cash burn rate of -$153.53M TTM and a debt-heavy balance sheet. The single most important tension is the disconnect between the current $5.24B market cap—implying blockbuster sales—and the reality of a pre-revenue company facing a pass/fail regulatory decision. The thesis will be definitively resolved by the FDA's verdict on gedatolisib.
Bullish
- Binary FDA Catalyst Imminent: The stock's entire valuation hinges on the upcoming FDA review and potential approval of its lead candidate, gedatolisib, for HR+/HER2- breast cancer. The pivotal Phase 3 VIKTORIA-1 trial has completed enrollment, creating a clear, high-impact near-term catalyst that has already driven a 1,185.86% annual return as anticipation builds.
- Strong Institutional Conviction: Major funds have made substantial, high-conviction bets, including a $170 million position, signaling deep-pocketed belief in the drug's approval and commercial potential. This institutional support provides capital stability and validates the underlying scientific thesis ahead of the binary event.
- Analyst Consensus Remains Bullish: Despite a recent downgrade to Neutral by HC Wainwright, the majority of the 7 covering analysts maintain Buy ratings. The average forward revenue estimate of $1.72 billion reflects significant commercial expectations, with a high-end target of $2.82 billion implying blockbuster potential.
- Robust Balance Sheet Liquidity: The company has a strong current ratio of 10.55, indicating ample short-term assets to cover liabilities and fund operations through the critical regulatory period. This financial runway reduces near-term dilution risk as it approaches the FDA decision.
Bearish
- Extreme Valuation on No Revenue: The company has zero revenue and deeply negative earnings, with a trailing EPS of -$0.96 and a Price-to-Book ratio of 52.11, which is astronomically high. This valuation reflects perfect execution and approval, leaving no margin for error and immense downside if the FDA decision is negative.
- Parabolic Price Run Risks Correction: Trading at $138.23, the stock is near its 52-week high of $151.02 after a 1,185.86% surge, positioning it 91.5% of the way from its low. This parabolic move suggests the stock is overextended and highly vulnerable to a sharp correction on any negative news or even approval being priced in.
- High Financial Burn & Leverage: The company is burning significant cash, with a quarterly net loss of $50.97 million and TTM free cash flow of -$153.53 million, funded by substantial leverage evidenced by a debt-to-equity ratio of 1.94. This creates financing risk and potential shareholder dilution if approval is delayed.
- Single-Asset, Binary Risk Profile: Celcuity's entire $5.24 billion market cap is tied to the success of one drug, gedatolisib. A clinical setback, unfavorable FDA review, or competitive threat in the HR+/HER2- breast cancer space could erase most of its value, as there is no diversified revenue stream to fall back on.
CELC Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +1185.86%. With a current price of $138.23, it is trading near the top of its 52-week range, approximately 91.5% of the distance from its 52-week low of $10.26 to its high of $151.02, indicating strong momentum but also raising concerns about potential overextension after such a parabolic move. Recent momentum remains robust but shows signs of volatility; the stock is up 12.91% over the past month and 31.91% over the past three months, though these gains are decelerating compared to the annual surge, suggesting the trend may be entering a consolidation phase as it digests its massive run. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $151.02 and support at the psychologically important $100 level, which aligns with recent consolidation; a breakout above $151 would signal a continuation of the bull run, while a breakdown below $100 could indicate a deeper correction, though the stock's remarkably low beta of 0.093 suggests it has traded with very low correlation to broader market volatility, which is unusual for a biotech and may reflect its unique, catalyst-driven price action.
Beta
0.09
0.09x market volatility
Max Drawdown
-27.7%
Largest decline past year
52-Week Range
$10-$151
Price range past year
Annual Return
+1185.9%
Cumulative gain past year
| Period | CELC Return | S&P 500 |
|---|---|---|
| 1m | +12.9% | +4.4% |
| 3m | +31.9% | +9.3% |
| 6m | +41.8% | +10.5% |
| 1y | +1185.9% | +28.8% |
| ytd | +37.5% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CELC Fundamental Analysis
As a pre-revenue clinical-stage biotech, Celcuity has no product sales, with revenue of $0 reported for the quarter ending December 31, 2025. The company's financials are entirely defined by its burn rate as it advances clinical trials, with a net loss of $50.97 million in Q4 2025 and an EPS of -$0.96, reflecting the high-cost nature of late-stage drug development. Profitability metrics are all negative or zero, with gross margin, operating margin, and net margin all at 0%, and EBITDA deeply negative at -$49.20 million for the quarter, though this burn is expected and necessary to fund the pivotal trials that are the core of its investment thesis. The balance sheet shows a strong current ratio of 10.55, indicating ample short-term liquidity, but a debt-to-equity ratio of 1.94 points to significant leverage used to fund operations; trailing twelve-month free cash flow is deeply negative at -$153.53 million, underscoring the company's dependence on external financing until it can potentially generate revenue from gedatolisib.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-153529000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CELC Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio, which is 0 due to the absence of revenue, making traditional multiples inapplicable and highlighting the speculative, binary nature of the investment based entirely on future potential. Peer comparison using standard multiples is not meaningful, as the stock's $5.24 billion market cap is pricing in the future commercial success of gedatolisib rather than current financials, placing it in a distinct category of high-risk, high-reward clinical-stage biotechs awaiting a pivotal regulatory catalyst. Historical context is provided by the Price-to-Book (PB) ratio, which at 52.11 is near the top of its historical range and astronomically high, signaling the market is assigning immense value to the company's intellectual property and clinical assets over its tangible book value, a clear reflection of optimistic expectations for FDA approval and blockbuster sales potential.
PE
-29.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -26x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-33.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and fundamental. As a pre-revenue clinical-stage biotech, Celcuity has no product sales and is entirely dependent on external capital to fund its -$153.53 million TTM free cash flow burn. The debt-to-equity ratio of 1.94 indicates significant leverage used to finance trials, increasing financial risk. Furthermore, profitability metrics are all negative or zero, with a net loss of $50.97 million in Q4 2025, meaning the company must continue burning cash at a high rate until and unless gedatolisib generates revenue, creating relentless dilution or refinancing pressure.
Market & Competitive Risks center on valuation compression and clinical competition. The stock's Price-to-Book ratio of 52.11 is astronomically high, reflecting near-perfect expectations. Any disappointment, even a delayed approval, could trigger a severe multiple contraction. The stock's low beta of 0.093 is deceptive; it indicates decoupling from the market but also highlights extreme sensitivity to idiosyncratic news. Competitors in the PI3K/AKT/mTOR pathway and the broader HR+/HER2- breast cancer treatment landscape could launch superior or cheaper therapies, undermining gedatolisib's commercial potential even if approved.
The Worst-Case Scenario involves a Complete Clinical or Regulatory Failure. A negative FDA decision, unexpected serious safety findings, or failed confirmatory trial data for gedatolisib would immediately invalidate the investment thesis. Given the lack of other revenue-generating assets, the stock could rapidly reprice to a fraction of its current value, potentially falling towards its 52-week low of $10.26 or even lower, as the cash burn would continue without a path to profitability. From the current price of $138.23, this scenario implies a catastrophic loss of approximately -93% to the 52-week low, effectively wiping out most of the capital invested at these levels.
FAQ
The key risks are, in order of severity: 1) Regulatory/Clinical Risk: FDA rejection or delay of gedatolisib, which would collapse the thesis (binary event risk). 2) Financial Risk: High cash burn (-$153.53M TTM) and leverage (debt-to-equity of 1.94) requiring dilutive financing. 3) Valuation Risk: The parabolic 1,185% gain and P/B of 52.11 leave the stock vulnerable to a sharp correction even on neutral news. 4) Concentration Risk: The entire company value is tied to one drug candidate with no diversified pipeline or revenue.
The 12-month forecast is highly bifurcated around the FDA decision. The base case (50% probability) sees the stock consolidating between $100 and $151 as it digests its massive run. The bull case (30% probability), driven by FDA approval and strong launch momentum, targets a range of $151 to $200. The bear case (20% probability), triggered by a regulatory setback, forecasts a collapse to a range of $10 to $50. The most likely scenario is the base case, as the extreme prior appreciation suggests the market has already priced in a high likelihood of success, limiting near-term upside without flawless execution.
Based on traditional financial metrics, CELC is dramatically overvalued. The company has no revenue, negative earnings (EPS of -$0.96), and a Price-to-Book ratio of 52.11, which is extraordinarily high. However, biotech stocks are valued on future potential, not current financials. The $5.24 billion market cap is the market's estimate of the net present value of gedatolisib's future sales. Therefore, it is neither overvalued nor undervalued in a traditional sense; it is appropriately valued for a perfect approval and launch scenario, but carries zero margin of safety for any deviation from that perfect path.
CELC is a good buy only for a very specific type of investor: one with a high risk tolerance, a deep understanding of biotech regulatory catalysts, and the ability to potentially lose a substantial portion of their investment. The stock has risen 1,185% in a year on FDA approval hopes, suggesting much of the positive outcome may be priced in at the current $138 level. While analyst targets imply significant revenue potential, the downside risk to the 52-week low of $10.26 (-93%) in a failure scenario is severe. It is not a good buy for most mainstream investors seeking stability or diversified growth.
CELC is suitable only for a short-to-medium-term, catalyst-driven investment horizon. The investment thesis will be largely resolved within the next 12-18 months by the FDA's decision and initial launch trajectory for gedatolisib. The stock's low beta of 0.093 and lack of dividends make it irrelevant for long-term income or stable growth. Given the binary nature, the minimum holding period is through the FDA catalyst, but investors should be prepared to exit quickly based on the news outcome. It is not a 'buy and hold forever' stock; it is a tactical, event-driven trade.